These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 10946880)

  • 1. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
    Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission and recurrence of hyperthyroid Graves' disease during and after methimazole treatment when assessed by IgE and interleukin 13.
    Komiya I; Yamada T; Sato A; Kouki T; Nishimori T; Takasu N
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3540-4. PubMed ID: 11502776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease].
    Sato A; Yamada T
    Nihon Rinsho; 1999 Aug; 57(8):1904-9. PubMed ID: 10483274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of methimazole treatment for 2 years on circulating IL-4, IgE, TBII, and TSAb in patients with hyperthyroid Graves' disease.
    Yamada T; Komiya I; Miyahara Y; Komatsu M; Shima I; Inazawa T; Aizawa T
    Endocr J; 2006 Dec; 53(6):783-8. PubMed ID: 16983180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A possible role of immunoglobulin E in patients with hyperthyroid Graves' disease.
    Sato A; Takemura Y; Yamada T; Ohtsuka H; Sakai H; Miyahara Y; Aizawa T; Terao A; Onuma S; Junen K; Kanamori A; Nakamura Y; Tejima E; Ito Y; Kamijo K
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3602-5. PubMed ID: 10523002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.
    Sato A; Yamada T; Aizawa T; Ichikawa K; Komiya I; Takasu N; Takemura Y
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
    Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
    J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
    Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of thyroid blood flow as a predictor of methimazole sensitivity in untreated hyperthyroid patients with Graves' disease.
    Nagasaki T; Inaba M; Kumeda Y; Fujiwara-Ueda M; Hiura Y; Nishizawa Y
    Biomed Pharmacother; 2007 Sep; 61(8):472-6. PubMed ID: 17420111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reappraisal of the 3,5,3'-triiodothyronine-suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves' disease.
    Yamada T; Koizumi Y; Sato A; Hashizume K; Aizawa T; Takasu N; Nagata H
    J Clin Endocrinol Metab; 1984 Apr; 58(4):676-80. PubMed ID: 6421866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An elevation of stem cell factor in patients with hyperthyroid Graves' disease.
    Yamada T; Sato A; Aizawa T; Ootsuka H; Miyahara Y; Sakai H; Terao A; Onuma S; Ito Y; Kanamori A; Nakamura Y; Tejima E
    Thyroid; 1998 Jun; 8(6):499-504. PubMed ID: 9669287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients.
    Tamai H; Hayaki I; Kawai K; Komaki G; Matsubayashi S; Kuma K; Kumagai LF; Nagataki S
    J Clin Endocrinol Metab; 1995 May; 80(5):1481-4. PubMed ID: 7744989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyrotropin binding inhibiting immunoglobulins (TBII) in Graves' disease, toxic nodular goitre and autoimmune thyroiditis.
    Wägar G; Mäkinen T; Lamberg BA; Gordin A; Apter L; Pekonen F
    Ann Clin Res; 1982 Apr; 14(2):83-9. PubMed ID: 6184007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
    Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
    Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of costimulatory molecules (CD28-CTLA-4/B7) expression on chosen mononuclear cells in adolescents with Graves' disease during methimazole therapy].
    Bossowski A; Stasiak-Barmuta A; Urban M; Rinderle C
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(2):93-101. PubMed ID: 15504312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
    Molnár I
    Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.
    Chen JJ; Ladenson PW
    J Clin Endocrinol Metab; 1986 Jul; 63(1):102-6. PubMed ID: 2423547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.